Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report)’s stock price dropped 5.3% during mid-day trading on Monday . The stock traded as low as $16.17 and last traded at $16.6250. 768,262 shares were traded during mid-day trading, a decline of 86% from the average session volume of 5,637,388 shares. The stock had previously closed at $17.56.
Analyst Ratings Changes
A number of brokerages have recently commented on NTLA. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Intellia Therapeutics in a report on Monday, June 15th. Chardan Capital upped their price objective on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Wall Street Zen lowered shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 21st. Finally, Morgan Stanley boosted their price target on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.46.
Read Our Latest Stock Analysis on Intellia Therapeutics
Intellia Therapeutics Stock Up 2.8%
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The company had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. During the same period last year, the company posted ($1.10) earnings per share. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Intellia Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Intellia Therapeutics in the third quarter valued at $30,000. Advisory Services Network LLC purchased a new position in shares of Intellia Therapeutics during the third quarter valued at $33,000. Headlands Technologies LLC acquired a new position in Intellia Therapeutics during the second quarter valued at $26,000. Comerica Bank raised its position in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the period. Finally, Danske Bank A S purchased a new stake in Intellia Therapeutics in the 3rd quarter worth about $50,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.
Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.
Read More
- Five stocks we like better than Intellia Therapeutics
- This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
- These 3 Stocks Offer Investors Exposure to the Functional Beverage Boom
- Alcoa’s $4.1 Billion South32 Deal: Opportunity Behind the 9% Drop
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
